Delcath Systems, Inc. (DCTH)

Market Cap	430.54M
Revenue (ttm)	53.85M
Net Income (ttm)	-14.21M
Shares Out	33.93M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	183.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	372,771
Open	12.65
Previous Close	12.51
Day's Range	12.43 - 12.90
52-Week Range	7.17 - 18.23
Beta	0.88
Analysts	Strong Buy
Price Target	24.00 (+89.13%)
Earnings Date	Aug 4, 2025

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: DCTH
• Website: https://www.delcath.com

Financial Performance

In 2024, Delcath Systems's revenue was $37.21 million, an increase of 1701.69% compared to the previous year's $2.07 million. Losses were -$26.39 million, -44.66% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price target is $24.0, which is an increase of 89.13% from the latest price.

Price Target

$24.0

(89.13% upside)

Analyst Consensus: Strong Buy